Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer

BACKGROUND: Lutetium-177 [(177)Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer. The presence of PSMA-negative/FDG-positive metastases can preclude patients from being eligible for this treatment. Biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaudreault, Mathieu, Chang, David, Hardcastle, Nicholas, Jackson, Price, Kron, Tomas, Hofman, Michael S., Siva, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040757/
https://www.ncbi.nlm.nih.gov/pubmed/36994211
http://dx.doi.org/10.3389/fonc.2023.1134884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040757/
https://www.ncbi.nlm.nih.gov/pubmed/36994211
http://dx.doi.org/10.3389/fonc.2023.1134884

Ejemplares similares